Basilea awarded $130 million for J&J's clinical development mistakes
This article was originally published in Scrip
Executive Summary
A Dutch arbitration court has ordered Johnson & Johnson to pay $130 million to Basilea Pharmaceutica for breach of its licensing agreement with the Swiss firm for the experimental antibiotic ceftobiprole (Zevtera) in the treatment of complicated skin and soft tissue infections (cSSTI).